Skip to main content

GSK vs Sanofi: Founders, CEOs and History

GSK was founded in 1715 by Silvanus Bevan, Joseph Nathan, John K. Smith and is led by Luke Miels. Sanofi was founded in 2004 by Jean-François Dehecq, René Sautier and is led by Belén Garijo.

Company facts

GSK

Founded
1715
Headquarters
London, United Kingdom
Current CEO
Luke Miels
Employees
66,800

Sanofi

Founded
2004
Headquarters
Paris, France
Current CEO
Belén Garijo
Employees
74,846

Founders

GSK

  • Silvanus Bevan

    Silvanus Bevan was a Quaker apothecary who opened a pharmacy at Plough Court in the City of London in 1715. The business later became Allen & Hanburys, a respiratory-medicine specialist that Glaxo acquired in 1958, which is why GSK dates its history to 1715.

  • Joseph Nathan

    Joseph Nathan emigrated from London to New Zealand and founded a general trading business in Wellington. In 1904 the firm began producing dried milk at Bunnythorpe and sold it as baby food under the Glaxo name.

  • John K. Smith

    John K. Smith opened a drugstore in Philadelphia in 1830. Mahlon Kline joined the business as a bookkeeper in 1865, it became Smith, Kline & Co. in 1875, and Smith, Kline & French after acquiring French, Richards & Co. in 1891.

  • Mahlon Kline

    Mahlon Kline joined John K. Smith's Philadelphia drug business as a bookkeeper in 1865 and became a partner as it grew into a wholesale and manufacturing company, renamed Smith, Kline & Co. in 1875.

  • Henry Wellcome

    Henry Wellcome was a US-born pharmacist who co-founded Burroughs Wellcome & Co. with Silas Burroughs in London in 1880. The company popularised compressed tablets under the 'Tabloid' trademark and later funded major research laboratories.

GSK founders in full

Sanofi

  • Jean-François Dehecq

    Jean-François Dehecq led Sanofi from its creation as Elf Aquitaine's health subsidiary in 1973. He drove the 1999 merger with Synthélabo and the 2004 takeover of Aventis, served as CEO of Sanofi-Aventis until the end of 2006 and remained chairman until 2010.

  • René Sautier

    René Sautier is credited alongside Jean-François Dehecq with setting up Sanofi as Elf Aquitaine's pharmaceutical arm in 1973. Public records on his later role are limited. (Exact birth year remains publicly undisclosed).

Sanofi founders in full

CEOs and their tenures

GSK

  1. Jean-Pierre Garnier2000–2008

    Former Chief Executive Officer

    Garnier executed one of the largest corporate mergers in pharmaceutical history, effectively creating the modern GSK conglomerate.

    Source
  2. Andrew Witty2008–2017

    Former Chief Executive Officer

    Witty provided steady leadership during a period of significant macroeconomic volatility following the 2008 financial crisis.

    Source
  3. Emma Walmsley2017–2025

    Former Chief Executive Officer

    Walmsley modernized a sprawling, inefficient corporate giant, transforming GSK into a focused, agile biopharmaceutical enterprise.

    Source
  4. Luke Miels2026–present

    Chief Executive Officer

    Joined GSK in 2017 as President of Global Pharmaceuticals and later served as Chief Commercial Officer before succeeding Emma Walmsley on January 1, 2026.

    Source
GSK CEO history in full

Sanofi

  1. Olivier Brandicourt2015–2019

    Chief Executive Officer

    Olivier Brandicourt served as chief executive of Sanofi S.A. from 2015 to 2019.

    Source
  2. Paul Hudson2019–2026

    Former Chief Executive Officer

    Grew Dupixent into a ~$17.7B (EUR15.7B) product; the board did not renew his mandate in February 2026 amid concerns over pipeline productivity.

    Source
  3. Belén Garijo2026–present

    Chief Executive Officer

    The board hired her to strengthen execution discipline and capital allocation. She previously led Merck KGaA and worked at Sanofi for 15 years.

    Source
  4. Olivier Charmeil2026–2026

    Interim Chief Executive Officer

    Provided continuity during the leadership transition.

    Source
Sanofi CEO history in full

Timeline: GSK and Sanofi side by side

  1. 1715GSK

    Silvanus Bevan opens Plough Court pharmacy

    Silvanus Bevan opens a pharmacy at Plough Court in London, the business that later became Allen & Hanburys and GSK's oldest root.

  2. 1830GSK

    John K. Smith opens a Philadelphia drugstore

    John K. Smith's Philadelphia drugstore is the start of the business that became Smith, Kline & French.

  3. 1880GSK

    Burroughs Wellcome & Co. founded

    Henry Wellcome and Silas Burroughs found Burroughs Wellcome & Co. in London.

  4. 1904GSK

    Glaxo dried milk launched in New Zealand

    Joseph Nathan & Co. begins producing dried milk at Bunnythorpe, New Zealand, sold under the Glaxo name.

  5. 1958GSK

    Glaxo acquires Allen & Hanburys

    Glaxo buys Allen & Hanburys, bringing the Plough Court lineage and a respiratory business into the group.

  6. 1973Sanofi

    Sanofi created inside Elf Aquitaine

    The French oil group sets up Sanofi as its healthcare subsidiary.

  7. 1995GSK

    Glaxo merges with Wellcome

    Glaxo acquires Wellcome plc to form Glaxo Wellcome.

  8. 1999Sanofi

    Sanofi-Synthélabo formed

    Sanofi merges with L'Oréal's pharmaceutical unit Synthélabo.

  9. 2000GSK

    GlaxoSmithKline formed

    Glaxo Wellcome and SmithKline Beecham merge in December 2000 to create GlaxoSmithKline, headquartered in the UK.

  10. 2004Sanofi

    Aventis takeover

    Sanofi-Synthélabo wins a hostile bid for the larger Aventis, creating Sanofi-Aventis.

  11. 2008Sanofi

    Chris Viehbacher Becomes CEO

    Chris Viehbacher became chief executive of Sanofi-Aventis in December 2008.

  12. 2011Sanofi

    Genzyme acquired

    Sanofi buys Genzyme for about $20.1 billion, adding rare disease therapies.

  13. 2015GSK

    Consumer healthcare joint venture with Novartis

    GSK and Novartis combine their consumer health businesses in a joint venture majority-owned by GSK, as part of an asset swap in which GSK sold its oncology portfolio to Novartis.

  14. 2017GSK

    Shingrix approved; Emma Walmsley becomes CEO

    Emma Walmsley becomes CEO in April 2017, and the FDA approves the Shingrix shingles vaccine in October 2017.

  15. 2017Sanofi

    Dupixent approved

    The FDA approves Dupixent for atopic dermatitis, starting Sanofi's largest growth franchise.

  16. 2019Sanofi

    'Play to Win' strategy

    New CEO Paul Hudson refocuses Sanofi on immunology, vaccines and specialty care.

  17. 2022GSK

    Haleon demerged

    GSK demerges its consumer health business as Haleon plc in July 2022 and shortens its name to GSK plc.

  18. 2023GSK

    Arexvy approved

    The FDA approves Arexvy in May 2023 as the first RSV vaccine for adults aged 60 and older.

  19. 2023Sanofi

    Acquired Provention Bio

    Sanofi acquired Provention Bio for $2.9 billion.

  20. 2025GSK

    Exdensur and Blenrep approved in the US

    GSK wins US approvals including Blujepa (March), Blenrep (October) and the twice-yearly asthma biologic Exdensur (December 2025).

  21. 2025Sanofi

    Opella control sold; Blueprint acquired

    Sanofi sells a 50% controlling stake in Opella to CD&R in April and completes the Blueprint Medicines acquisition in July.

  22. 2026GSK

    Luke Miels becomes CEO

    Luke Miels succeeds Emma Walmsley as Chief Executive Officer on January 1, 2026.

  23. 2026GSK

    Nuvalent acquisition completed

    GSK completes its $10.6 billion acquisition of Nuvalent in July 2026, adding the lung-cancer drugs Jideytro and neladalkib.

  24. 2026Sanofi

    Belén Garijo becomes CEO

    The board ends Paul Hudson's tenure in February; Garijo takes over after the April 29 AGM.

  25. 2026Sanofi

    Olivier Charmeil Named Interim CEO

    Olivier Charmeil served as interim chief executive of Sanofi in 2026 between Paul Hudson and Belen Garijo.

Acquisitions

GSK

  • Nuvalent2026$10.6B
  • efimosfermin alfa (from Boston Pharmaceuticals)2025$1.2B
  • IDRx2025$1B
  • Sierra Oncology2022$1.9B
All GSK acquisitions

Sanofi

  • Blueprint Medicines2025$9.1B
  • Provention Bio2023$2.9B
  • Genzyme2011$20.1B
  • Aventis2004Undisclosed
All Sanofi acquisitions

Questions about GSK vs Sanofi

Who is the CEO of GSK plc and Sanofi S.A.?

GSK plc is led by Luke Miels and Sanofi S.A. is led by Belén Garijo. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was GSK plc founded vs Sanofi S.A.?

GSK plc was founded in 1715 — 289 years before Sanofi S.A., which was founded in 2004. GSK plc's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Sanofi S.A..

How many employees does GSK plc have compared to Sanofi S.A.?

GSK plc employs approximately 66,800 people, while Sanofi S.A. employs approximately 74,846. Sanofi S.A. has the larger workforce at 74,846 employees, compared to GSK plc's 66,800. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are GSK plc and Sanofi S.A. headquartered?

GSK plc is headquartered in United Kingdom and Sanofi S.A. is headquartered in France. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.

Who founded GSK plc and Sanofi S.A.?

GSK plc was founded by Silvanus Bevan, Joseph Nathan, John K. Smith, Mahlon Kline, Henry Wellcome. Sanofi S.A. was founded by Jean-François Dehecq, René Sautier.

Which company has a longer operating history — GSK plc or Sanofi S.A.?

GSK plc has been operating for approximately 311 years, making it the more established of the two companies. Sanofi S.A. has been in operation for around 22 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the GSK vs Sanofi overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.